ArticleFrontiers in oncology2025
Case Report: A rare case of cervical lymph node metastasis from prostate cancer suspicious for combined lung cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical lymph node metastasis as the initial manifestation of prostate cancer is uncommon, and the diagnostic and therapeutic processes become considerably more complex when primary lung malignancy is also suspected. Immunohistochemical (IHC) techniques are critical in the diagnosis of multiple primary malignancies, in particular when histopathologic access is limited. We report on a 74-year-old male patient who presented with respiratory symptoms. Computed tomography revealed a 6.4-cm × 4.7-cm mass in the upper lobe of the right lung with cervical lymph node metastasis. The initial diagnosis of metastatic adenocarcinoma was established by cervical lymph node biopsy. During follow-up, the patient developed progressive dysuria, and prostate cancer was ultimately confirmed by prostate biopsy. IHC analysis of the cervical lymph node specimen revealed the following profile: prostate-specific antigen (PSA) (focally positive, 3+), P504S (diffusely positive, 3+), TTF1 (-), CK7 (-), CK20 (-), napsin A (-), and P40 (-). This IHC profile definitively established the prostatic origin of the metastatic carcinoma in the cervical lymph node. This case highlights the value of employing therapeutic diagnostic strategies when definitive histopathologic access is challenging and provides insights into the management of atypical metastatic prostate cancer and multiple primary cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.